Public health impact and cost-effectiveness of catch-up 9-valent HPV vaccination of individuals through age 45 years in the United States

Public health impact and cost-effectiveness of catch-up 9-valent HPV vaccination of individuals through age 45 years in the United States

The Advisory Committee on Immunization Practices (ACIP) recommended catch-up 9-valent Human Papillomavirus (HPV) vaccination through age 26 years, and shared clinical decision-making for adults aged 27–45 years, compared with catch-up through age 26 years and 21 years for females and males, respecti...

Full description

Bibliographic Details
Main Authors: Vincent Daniels, Vimalanand S. Prabhu, Cody Palmer, Salome Samant, Smita Kothari, Craig Roberts, Elamin Elbasha
Format: Article
Language:English
Published: Taylor & Francis Group 2021-07-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
cost-effectiveness
disease transmission models
9-valent human papillomavirus (hpv) vaccine
adult
united states
Online Access:http://dx.doi.org/10.1080/21645515.2020.1852870

Internet

http://dx.doi.org/10.1080/21645515.2020.1852870

Similar Items